<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03998735</url>
  </required_header>
  <id_info>
    <org_study_id>SPH-2019-23251</org_study_id>
    <secondary_id>2019NTLS123</secondary_id>
    <nct_id>NCT03998735</nct_id>
    <nct_alias>NCT02499198</nct_alias>
  </id_info>
  <brief_title>Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure</brief_title>
  <official_title>Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our goal in this study is to investigate the extent of endogenous nitrosation of nornicotine&#xD;
      in smokeless tobacco users as a function of nornicotine content in smokeless products. This&#xD;
      study will lead to an understanding of the endogenous formation of NNN from nornicotine in&#xD;
      humans, and will also investigate the effect of the reduction of nornicotine content in&#xD;
      smokeless tobacco on the extent of endogenous NNN formation. The knowledge gained in this&#xD;
      study will lead to the development of recommendations for the regulation, or potentially&#xD;
      elimination, of nornicotine in smokeless tobacco products in order to minimize exposure to&#xD;
      NNN in the users of these products.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate endogenous formation of NNN in smokeless tobacco users.</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Presence of urinary [pyridine-D4]NNN ([D4]NNN)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate endogenous formation of NNN in smokeless tobacco users.</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Level of urinary [pyridine-D4]NNN ([D4]NNN) present</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Smokeless Tobacco</condition>
  <arm_group>
    <arm_group_label>Group 1 (N=15)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>160 µg/g herbal snuff, median level found in commercial moist snuff</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (N=15)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>70 µg/g herbal snuff, lowest level found in commercial moist snuff (rounded)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 (N=15)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.5 µg/g herbal snuff, 5% of the lowest level found in commercial moist snuff</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4(N=10)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0 µg/g herbal snuff, control group will use unmodified herbal snuff</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herbal Snuff (Smokeless Tobacco)</intervention_name>
    <description>4 levels of [D4]nornicotine in herbal snuff</description>
    <arm_group_label>Group 1 (N=15)</arm_group_label>
    <arm_group_label>Group 2 (N=15)</arm_group_label>
    <arm_group_label>Group 3 (N=15)</arm_group_label>
    <arm_group_label>Group 4(N=10)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female adult smokeless tobacco users 18-65 years of age, using at least 3 tins&#xD;
             of product per week for 6 months;&#xD;
&#xD;
          -  Used the same brand for &gt;80% of their smokeless tobacco use over the course of at&#xD;
             least 6 months, and used this brand exclusively for at least two weeks prior to the&#xD;
             eligibility screening;&#xD;
&#xD;
          -  Not smoking or using any other nicotine or tobacco product in the past 2 weeks&#xD;
             (expired CO &lt; 6 ppm);&#xD;
&#xD;
          -  Participants are in good physical health (no unstable medical condition) and good&#xD;
             general oral health as determined by the licensed medical professional;&#xD;
&#xD;
          -  Participants are in stable, good mental health (e.g. not currently, within the past 6&#xD;
             months, experiencing unstable or untreated psychiatric diagnosis, including substance&#xD;
             abuse) as determined by the licensed medical professional;&#xD;
&#xD;
          -  Participants who are not taking any medications that affect relevant metabolic&#xD;
             enzymes;&#xD;
&#xD;
          -  Women who are not pregnant or nursing or planning to become pregnant;&#xD;
&#xD;
          -  Participants have provided written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant immune system disorders, respiratory diseases, kidney or liver diseases or&#xD;
             any other medical disorders that may affect biomarker data as determined by the&#xD;
             licensed medical professional;&#xD;
&#xD;
          -  Vital signs out of range as determined by the licensed medical professional&#xD;
             (participants failing for vital signs will be allowed to re-screen once):&#xD;
&#xD;
          -  Evident poor oral health (significant gum recession, dental caries, tooth loss) as&#xD;
             determined by the general oral health status check;&#xD;
&#xD;
          -  Excessive drinking (e.g., 5 or more drinks daily) or problems with drinking or drugs&#xD;
             (e.g., self-report of binge drinking alcohol or treatment for drug or alcohol abuse&#xD;
             within last 3 months); to be assessed by PI or licensed medical professional;&#xD;
&#xD;
          -  Regular smoking or tobacco use (e.g., greater than once a week) other than oral&#xD;
             smokeless tobacco products;&#xD;
&#xD;
          -  Currently (within the past 2 weeks) using nicotine replacement or other tobacco&#xD;
             cessation products (to minimize confounding effects of another product);&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irina Stepanov, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota, Division of Environmental Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanna Vanderloo, RN, MSN</last_name>
    <phone>612-624-4983</phone>
    <email>hannav@umn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lobeline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

